Is GALT or PURR more profitable?

Galectin Therapeutics' return on equity of 0.00% beat Hyperliquid Strategies' return on equity. Company Net Margins Return on Equity Return on Assets Galectin Therapeutics N/A N/A -164.69% Hyperliquid Strategies N/A -56.04% -52.22%

Does the media prefer GALT or PURR?

In the previous week, Hyperliquid Strategies had 2 more articles in the media than Galectin Therapeutics. MarketBeat recorded 5 mentions for Hyperliquid Strategies and 3 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.93 beat Hyperliquid Strategies' score of 0.65 indicating that Galectin Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hyperliquid Strategies 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, CGEM or GALT?

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cullinan Therapeutics N/A N/A -$219.88M -$3.36 N/A Galectin Therapeutics N/A N/A -$30.84M -$0.41 N/A

Is CGEM or GALT more profitable?

Galectin Therapeutics' return on equity of 0.00% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cullinan Therapeutics N/A -51.45% -47.64% Galectin Therapeutics N/A N/A -164.69%

Does the media refer more to CGEM or GALT?

In the previous week, Cullinan Therapeutics had 1 more articles in the media than Galectin Therapeutics. MarketBeat recorded 4 mentions for Cullinan Therapeutics and 3 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.93 beat Cullinan Therapeutics' score of 0.87 indicating that Galectin Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Galectin Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, OLMA or GALT?

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Olema Pharmaceuticals N/A N/A -$162.45M -$2.02 N/A Galectin Therapeutics N/A N/A -$30.84M -$0.41 N/A

Is OLMA or GALT more profitable?

Galectin Therapeutics' return on equity of 0.00% beat Olema Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Olema Pharmaceuticals N/A -46.00% -41.22% Galectin Therapeutics N/A N/A -164.69%

Does the media prefer OLMA or GALT?

In the previous week, Galectin Therapeutics had 1 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 3 mentions for Galectin Therapeutics and 2 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 1.07 beat Galectin Therapeutics' score of 0.93 indicating that Olema Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Galectin Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor XNCR or GALT?

In the previous week, Xencor had 4 more articles in the media than Galectin Therapeutics. MarketBeat recorded 7 mentions for Xencor and 3 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.93 beat Xencor's score of 0.65 indicating that Galectin Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Galectin Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, GALT or ORIC?

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galectin Therapeutics N/A N/A -$30.84M -$0.41 N/A Oric Pharmaceuticals N/A N/A -$129.47M -$1.44 N/A

Is GALT or ORIC more profitable?

Galectin Therapeutics' return on equity of 0.00% beat Oric Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Galectin Therapeutics N/A N/A -164.69% Oric Pharmaceuticals N/A -35.33% -33.31%

Does the media favor GALT or ORIC?

In the previous week, Galectin Therapeutics and Galectin Therapeutics both had 3 articles in the media. Oric Pharmaceuticals' average media sentiment score of 1.77 beat Galectin Therapeutics' score of 0.93 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oric Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Galectin Therapeutics (GALT) Competitors

$4.60 +0.54 (+13.30%)

As of 07/13/2026 04:00 PM Eastern

Compare

GALT vs. PURR, CGEM, OLMA, XNCR, and ORIC

Should you buy Galectin Therapeutics stock or one of its competitors? MarketBeat compares Galectin Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Galectin Therapeutics include Hyperliquid Strategies (PURR), Cullinan Therapeutics (CGEM), Olema Pharmaceuticals (OLMA), Xencor (XNCR), and Oric Pharmaceuticals (ORIC). These companies are all part of the "pharmaceutical products" industry.

How does Galectin Therapeutics compare to Hyperliquid Strategies?

Galectin Therapeutics (NASDAQ:GALT) and Hyperliquid Strategies (NASDAQ:PURR) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

11.7% of Galectin Therapeutics shares are held by institutional investors. Comparatively, 9.5% of Hyperliquid Strategies shares are held by institutional investors. 52.6% of Galectin Therapeutics shares are held by company insiders. Comparatively, 8.5% of Hyperliquid Strategies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Galectin Therapeutics presently has a consensus target price of $11.00, suggesting a potential upside of 139.13%. Hyperliquid Strategies has a consensus target price of $12.72, suggesting a potential upside of 77.61%. Given Galectin Therapeutics' higher possible upside, analysts clearly believe Galectin Therapeutics is more favorable than Hyperliquid Strategies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Hyperliquid Strategies has higher revenue and earnings than Galectin Therapeutics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A
Hyperliquid Strategies	$1M	1,034.26	-$16.01M	-$7.37	N/A

Galectin Therapeutics has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Hyperliquid Strategies has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market.

Galectin Therapeutics' return on equity of 0.00% beat Hyperliquid Strategies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-164.69%
Hyperliquid Strategies	N/A	-56.04%	-52.22%

In the previous week, Hyperliquid Strategies had 2 more articles in the media than Galectin Therapeutics. MarketBeat recorded 5 mentions for Hyperliquid Strategies and 3 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.93 beat Hyperliquid Strategies' score of 0.65 indicating that Galectin Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galectin Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hyperliquid Strategies	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Hyperliquid Strategies beats Galectin Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Galectin Therapeutics compare to Cullinan Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A

Galectin Therapeutics' return on equity of 0.00% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-51.45%	-47.64%
Galectin Therapeutics	N/A	N/A	-164.69%

In the previous week, Cullinan Therapeutics had 1 more articles in the media than Galectin Therapeutics. MarketBeat recorded 4 mentions for Cullinan Therapeutics and 3 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.93 beat Cullinan Therapeutics' score of 0.87 indicating that Galectin Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Galectin Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cullinan Therapeutics has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

Cullinan Therapeutics presently has a consensus price target of $32.00, suggesting a potential upside of 79.07%. Galectin Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 139.13%. Given Galectin Therapeutics' higher possible upside, analysts plainly believe Galectin Therapeutics is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

86.3% of Cullinan Therapeutics shares are held by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are held by institutional investors. 8.6% of Cullinan Therapeutics shares are held by insiders. Comparatively, 52.6% of Galectin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Galectin Therapeutics beats Cullinan Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Galectin Therapeutics compare to Olema Pharmaceuticals?

Olema Pharmaceuticals (NASDAQ:OLMA) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.02	N/A
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A

91.8% of Olema Pharmaceuticals shares are held by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are held by institutional investors. 12.6% of Olema Pharmaceuticals shares are held by company insiders. Comparatively, 52.6% of Galectin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Olema Pharmaceuticals has a beta of 2, meaning that its stock price is 100% more volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

In the previous week, Galectin Therapeutics had 1 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 3 mentions for Galectin Therapeutics and 2 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 1.07 beat Galectin Therapeutics' score of 0.93 indicating that Olema Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Galectin Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Olema Pharmaceuticals currently has a consensus target price of $44.10, suggesting a potential upside of 272.15%. Galectin Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 139.13%. Given Olema Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Galectin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Galectin Therapeutics' return on equity of 0.00% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-46.00%	-41.22%
Galectin Therapeutics	N/A	N/A	-164.69%

Summary

Olema Pharmaceuticals beats Galectin Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Galectin Therapeutics compare to Xencor?

Xencor (NASDAQ:XNCR) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

Galectin Therapeutics has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Galectin Therapeutics' return on equity of 0.00% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-177.10%	-28.77%	-20.52%
Galectin Therapeutics	N/A	N/A	-164.69%

11.7% of Galectin Therapeutics shares are owned by institutional investors. 5.1% of Xencor shares are owned by company insiders. Comparatively, 52.6% of Galectin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Xencor has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

Galectin Therapeutics has lower revenue, but higher earnings than Xencor. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$125.58M	8.83	-$91.92M	-$2.29	N/A
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A

Xencor currently has a consensus target price of $24.25, suggesting a potential upside of 62.10%. Galectin Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 139.13%. Given Galectin Therapeutics' higher probable upside, analysts plainly believe Galectin Therapeutics is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Xencor had 4 more articles in the media than Galectin Therapeutics. MarketBeat recorded 7 mentions for Xencor and 3 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.93 beat Xencor's score of 0.65 indicating that Galectin Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Galectin Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Galectin Therapeutics beats Xencor on 8 of the 15 factors compared between the two stocks.

How does Galectin Therapeutics compare to Oric Pharmaceuticals?

Galectin Therapeutics (NASDAQ:GALT) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A

Galectin Therapeutics has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market.

In the previous week, Galectin Therapeutics and Galectin Therapeutics both had 3 articles in the media. Oric Pharmaceuticals' average media sentiment score of 1.77 beat Galectin Therapeutics' score of 0.93 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galectin Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oric Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Galectin Therapeutics' return on equity of 0.00% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-164.69%
Oric Pharmaceuticals	N/A	-35.33%	-33.31%

Galectin Therapeutics currently has a consensus target price of $11.00, indicating a potential upside of 139.13%. Oric Pharmaceuticals has a consensus target price of $19.27, indicating a potential upside of 84.25%. Given Galectin Therapeutics' higher possible upside, equities research analysts clearly believe Galectin Therapeutics is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are owned by institutional investors. 52.6% of Galectin Therapeutics shares are owned by insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Oric Pharmaceuticals beats Galectin Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Galectin Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GALT vs. The Competition

Export

Metric	Galectin Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$267.38M	$3.05B	$7.05B	$12.61B
Dividend Yield	N/A	2.06%	2.68%	8.00%
P/E Ratio	-11.22	19.17	27.11	24.26
Price / Sales	N/A	838.79	589.14	117.88
Price / Cash	N/A	56.80	29.22	49.36
Price / Book	-2.31	4.22	10.75	6.29
Net Income	-$30.84M	$64.26M	$3.58B	$330.66M
7 Day Performance	-0.22%	-3.58%	-2.10%	-1.35%
1 Month Performance	72.28%	2.12%	3.29%	-0.64%
1 Year Performance	61.40%	20.35%	26.32%	19.08%

Galectin Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GALT Galectin Therapeutics	1.9542 of 5 stars	$4.60 +13.3%	$11.00 +139.1%	+83.3%	$267.38M	N/A	N/A	9
PURR Hyperliquid Strategies	2.4207 of 5 stars	$8.08 -8.4%	$12.72 +57.4%	N/A	$1.17B	$1M	N/A	N/A	Gap Down
CGEM Cullinan Therapeutics	2.5962 of 5 stars	$17.93 +0.7%	$32.00 +78.5%	+132.1%	$1.11B	N/A	N/A	30
OLMA Olema Pharmaceuticals	2.3471 of 5 stars	$12.40 -2.9%	$44.10 +255.6%	+154.8%	$1.10B	N/A	N/A	70	Analyst Upgrade
XNCR Xencor	2.2313 of 5 stars	$14.75 -1.0%	$24.25 +64.5%	+69.4%	$1.09B	$125.58M	N/A	280	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GALT) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Galectin Therapeutics (GALT) Competitors

GALT vs. PURR, CGEM, OLMA, XNCR, and ORIC

How does Galectin Therapeutics compare to Hyperliquid Strategies?

Summary

How does Galectin Therapeutics compare to Cullinan Therapeutics?

Summary

How does Galectin Therapeutics compare to Olema Pharmaceuticals?

Summary

How does Galectin Therapeutics compare to Xencor?

Summary

How does Galectin Therapeutics compare to Oric Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT vs. The Competition

Galectin Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Galectin Therapeutics (GALT) Competitors

GALT vs. PURR, CGEM, OLMA, XNCR, and ORIC

How does Galectin Therapeutics compare to Hyperliquid Strategies?

Do insiders & institutionals hold more shares of GALT or PURR?

Do analysts recommend GALT or PURR?

Which has stronger earnings and valuation, GALT or PURR?

Which has more volatility and risk, GALT or PURR?

Is GALT or PURR more profitable?

Does the media prefer GALT or PURR?

Summary

How does Galectin Therapeutics compare to Cullinan Therapeutics?

Which has stronger valuation & earnings, CGEM or GALT?

Is CGEM or GALT more profitable?

Does the media refer more to CGEM or GALT?

Which has more risk and volatility, CGEM or GALT?

Do analysts recommend CGEM or GALT?

Do institutionals & insiders hold more shares of CGEM or GALT?

Summary

How does Galectin Therapeutics compare to Olema Pharmaceuticals?

Which has better earnings and valuation, OLMA or GALT?

Do insiders & institutionals hold more shares of OLMA or GALT?

Which has more volatility and risk, OLMA or GALT?

Does the media prefer OLMA or GALT?

Do analysts recommend OLMA or GALT?

Is OLMA or GALT more profitable?

Summary

How does Galectin Therapeutics compare to Xencor?

Is XNCR or GALT more profitable?

Do insiders and institutionals hold more shares of XNCR or GALT?

Which has more volatility & risk, XNCR or GALT?

Which has better valuation and earnings, XNCR or GALT?

Do analysts recommend XNCR or GALT?

Does the media favor XNCR or GALT?

Summary

How does Galectin Therapeutics compare to Oric Pharmaceuticals?

Which has better valuation and earnings, GALT or ORIC?

Which has more risk & volatility, GALT or ORIC?

Does the media favor GALT or ORIC?

Is GALT or ORIC more profitable?

Do analysts rate GALT or ORIC?

Do institutionals & insiders believe in GALT or ORIC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT vs. The Competition

Galectin Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools